KRTX Company Profile and Key Details
NASDAQ : KRTX
Karuna Therapeutics
$329.83
0.09+0.03%
Open: 4:00 PMNot Actively Trading
74.07
BESG ScoreESG Rating
Price Chart
Stock Price Today
Karuna Therapeutics, Inc. (KRTX) stock surged +0.03%, trading at $329.83 on NASDAQ, up from the previous close of $329.74. The stock opened at $329.75, fluctuating between $329.75 and $329.97 in the recent session.
Stock Snapshot
329.74
Prev. Close
12.6B
Market Cap
329.75
Day Low
-28.094548551959114
P/E Ratio
-11.74
EPS (TTM)
-10.29
Cash Flow per Share
329.75
Open
38.2M
Number of Shares
329.97
Day High
94.94%
Free Float in %
33.2
Book Value
1.28M
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
Annual Report (10-k)
Stock Price History Chart
Contact Details
About Company
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Company Information
| Employees | 339 |
| Beta | 1.15 |
| Sales or Revenue | $654.00K |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
ARGX
7.94+0.94%
argenx SE$854.99REGN19.25+2.57%
Regeneron Pharmaceuticals, Inc.$767.96MDGL46.61+8.56%
Madrigal Pharmaceuticals, Inc.$591.02UTHR10.13+2.00%
United Therapeutics Corporation$517.13VRTX8.82+1.97%
Vertex Pharmaceuticals Incorporated$456.20ALNY4.19+1.06%
Alnylam Pharmaceuticals, Inc.$400.23PRAX3.66001+1.36%
Praxis Precision Medicines, Inc.$272.92KRYS7.43+3.18%
Krystal Biotech, Inc.$240.80SGEN-0.16-0.07%
Seagen Inc.$228.74CDTX0.45+0.20%
Cidara Therapeutics, Inc.$220.80Company Overview
Karuna Therapeutics, Inc. (NASDAQ:KRTX) closed at $329.83 USD, gaining $0.09 (0.03%) from the previous close of $329.74. The stock is currently trading near its 52-week high $158.38 and $329.99. With a market capitalization of about $12.60 billion, Karuna Therapeutics, Inc. is classified as a large-cap and shows market-like volatility (beta ~1.15). Key stats such as the average daily volume over the past year has been around 971.83 thousand shares, in line with its 52-week average. Headquartered in Boston, MA, Karuna Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO William Meury, the company employs approximately 339 people and listed since June 28, 2019. Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions.
Earnings & Analyst Outlook
Karuna Therapeutics, Inc. generated EPS of -$10.93 over the past year. Five-year average earnings growth is -102.34%. The latest quarter delivered EPS of -$2.80. The next quarter is forecast at -$2.69. Next year's EPS is expected at $1.78. Karuna Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 02, 2024, missed forecasts by -6.67%. The prior quarter beat by 14.02%. Over the last six quarters, Apple has recorded several small beats. These include -1.33% in February 23, 2023.
Financial & Profitability Overview
On valuation metrics, Karuna Therapeutics trades at a P/E of -28.11, P/S of 19264.95 and P/B of 9.72. The current ratio is 19.31 and quick ratio is 18.82. Operationally, the company’s inventory turnover is 0.05 and cash conversion cycle is 8324.08 days. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -23.12.
Quarterly Financial Highlights
The company ended the quarter with $1.26B in cash and short-term investments, a total debt of $16.69M, and net debt of - $169.14M. Total assets were $1.34B, with equity of $1.25B. Financials further reflected weakness, with operating cash flow of - $385.82M, free cash flow of - $388.74M, and capital expenditures of - $2.92M.
Price Forecast & Outlook
Our AI price prediction model suggests that Karuna Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.67%, with price expected at $345.22 by April 01, 2024, within a range of $340.84 to $349.63 3-Month Outlook: Projected rise of 114.26%, reaching $706.71 by June 14, 2024, with a range of $703.06 to $710.35. 1-Year Outlook: Projected gain of 111.14%, with price at $696.41 by March 18, 2025, within a range of $682.04 to $710.99.
Key Takeaways
Karuna Therapeutics, Inc. (NASDAQ:KRTX) shares are flat 0.91% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Karuna Therapeutics, Inc. trading at a premium to the broader market with a P/E of -28.11. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $215.78, suggesting -34.58% downside. Our AI forecast model points to short-term strength (4.67% over two weeks), a medium-term rise (114.26% over three months), and a longer-term gain (111.14% over one year), with expected trading ranges indicating moderate volatility.
Frequently Asked Questions
What is the current Karuna Therapeutics, Inc. (KRTX) stock price?
Karuna Therapeutics, Inc. (NASDAQ: KRTX) stock price is $329.83 in the last trading session. During the trading session, KRTX stock reached the peak price of $329.97 while $329.75 was the lowest point it dropped to. The percentage change in KRTX stock occurred in the recent session was 0.03% while the dollar amount for the price change in KRTX stock was $0.09.
KRTX's industry and sector of operation?
The NASDAQ listed KRTX is part of Biotechnology industry that operates in the broader Healthcare sector. Karuna Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of KRTX?
Dr. Troy A. Ignelzi
Chief Financial Officer & Sec.
Mr. Jason Parker Brown
Chief Financial Officer
Dr. Steven M. Paul M.D.
Pres of R&D, Chief Scientific Officer & Director
Ms. Charmaine Lykins
Chief Commercial Officer
Mr. Jonathan Rosin
Chief HR Officer
Dr. Stephen K. Brannan
Chief Medical Officer
Dr. Ronald N. Marcus M.D.
Senior Vice President of Medical
Mr. William Meury
Pres, Chief Executive Officer & Director
Mr. William P. Kane Jr.
Chief Commercial Officer
Ms. Mia Kelley J.D.
Vice President of Legal Affairs
Dr. Alan Breier
Chair of Scientific Advisory Board & Chief Clinical Advisor
Ms. Stephanie Moore
Vice President of HR
Dr. Andrew Craig Miller
Co-Founder & Chief Operating Officer
Chief Financial Officer & Sec.
Mr. Jason Parker Brown
Chief Financial Officer
Dr. Steven M. Paul M.D.
Pres of R&D, Chief Scientific Officer & Director
Ms. Charmaine Lykins
Chief Commercial Officer
Mr. Jonathan Rosin
Chief HR Officer
Dr. Stephen K. Brannan
Chief Medical Officer
Dr. Ronald N. Marcus M.D.
Senior Vice President of Medical
Mr. William Meury
Pres, Chief Executive Officer & Director
Mr. William P. Kane Jr.
Chief Commercial Officer
Ms. Mia Kelley J.D.
Vice President of Legal Affairs
Dr. Alan Breier
Chair of Scientific Advisory Board & Chief Clinical Advisor
Ms. Stephanie Moore
Vice President of HR
Dr. Andrew Craig Miller
Co-Founder & Chief Operating Officer
How KRTX did perform over past 52-week?
KRTX's closing price is 108.26% higher than its 52-week low of $158.38 where as its distance from 52-week high of $329.99 is -0.05%.
How many employees does KRTX have?
Number of KRTX employees currently stands at 339.
Link for KRTX official website?
Official Website of KRTX is: https://www.karunatx.com
How do I contact KRTX?
KRTX could be contacted at phone 857 449 2244 and can also be accessed through its website. KRTX operates from 99 High Street, Boston, MA 02110, United States.
How many shares of KRTX are traded daily?
KRTX stock volume for the day was 1.28M shares. The average number of KRTX shares traded daily for last 3 months was 971.83K.
What is the market cap of KRTX currently?
The market value of KRTX currently stands at $12.60B with its latest stock price at $329.83 and 38.2M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep